Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Pharmacokinetics and Dosimetry of [⁶⁸Ga]Ga-PSMA-11 in Chinese Participants with Progressive Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study.","authors":"Wei Fan, Yonghong Li, Hongcheng Shi, Jianming Guo, Rui Huang, Qiang Dong, Zhi Yang, Yong Yang, Xinlu Wang, Di Gu, Dingwei Ye, Feng Wang, Jing Wang, Danfeng Xu, Zhiqiang Jiang, Haifu Li, Jialu Li, Runqin Li, Li Huo, Zhigang Ji","doi":"10.1177/10849785251415122","DOIUrl":"10.1177/10849785251415122","url":null,"abstract":"<p><strong>Introduction: </strong>[⁶⁸Ga]Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging has demonstrated clinical value for individuals with prostate cancer (PC). In this phase 2 study, we measured the pharmacokinetics and dosimetry of [⁶⁸Ga]Ga-PSMA-11 in Chinese participants.</p><p><strong>Methods: </strong>Adult Chinese participants with progressive metastatic castration-resistant PC (mCRPC) received a single intravenous [⁶⁸Ga]Ga-PSMA-11 dose of approximately 150 MBq. Blood samples were collected at 5, 15, 30, 45, 85, 175, and 245 min post injection for pharmacokinetics assessments. Whole-body PET scans and low/ultra-low-dose CT scans were acquired at 30, 60, 120, and 255 min post injection for dosimetry assessments.</p><p><strong>Results: </strong>Pharmacokinetics and dosimetry assessments were completed in seven participants who received a [⁶⁸Ga]Ga-PSMA-11 dose (range: 108.3-236.7 MBq). In the blood, the geometric mean effective terminal half-life was 1.34 h (geometric coefficient of variation [geo-CV], 182%); geometric mean clearance was 9.80 L/h (geo-CV, 106%). The highest absorbed doses were seen in the kidneys, urinary bladder walls, and lacrimal glands. In the study population, the geometric mean (geo-CV) effective dose of [⁶⁸Ga]Ga-PSMA-11 was 4.2 mSv (32.9%).</p><p><strong>Conclusions: </strong>The pharmacokinetic and dosimetry profiles of [⁶⁸Ga]Ga-PSMA-11, assessed using a validated method in participants with progressive mCRPC, make it very suitable with proves its suitability.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"430-438"},"PeriodicalIF":1.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146196008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Locoregional Therapy Combined with Immune Checkpoint Blockade for Intermediate-Advanced Hepatocellular Carcinoma.","authors":"Xiaoyu Liu, Sheng Zheng, Juan Yang, Jiao Li, Cui Deng, Simin Zhang, Lili Shen","doi":"10.1177/10849785261453478","DOIUrl":"https://doi.org/10.1177/10849785261453478","url":null,"abstract":"<p><strong>Background: </strong>The potential value of combining transarterial chemoembolization (TACE) with immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) at intermediate-to-advanced stages remains incompletely defined. This study sought to characterize the efficacy and tolerability of this combined approach and to delineate pretreatment characteristics linked to patient prognosis.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 248 consecutive HCC patients managed between January 2020 and December 2024. Treatment allocation at the time of initial decision resulted in 126 patients receiving TACE in conjunction with ICIs, whereas 122 were managed with TACE as the sole intervention. Radiological response was independently adjudicated according to the modified Response Evaluation Criteria in Solid Tumors. Survival endpoints-namely progression-free survival (PFS) and overall survival (OS)-were derived via the Kaplan-Meier methodology, with prognostic determinants explored through Cox regression modeling.</p><p><strong>Results: </strong>The addition of ICIs to TACE conferred a substantially higher objective response rate (46.0% vs. 24.6%, <i>p</i> < 0.001) and disease control rate (77.8% vs. 59.8%, <i>p</i> = 0.003). The combination arm demonstrated a median PFS of 10.8 months, compared with 5.6 months in patients receiving TACE alone (<i>p</i> < 0.001); corresponding median OS figures were 21.6 and 14.2 months (<i>p</i> < 0.001). On multivariate Cox analysis, an Eastern Cooperative Oncology Group (ECOG) performance status of 2, serum α-fetoprotein (AFP) ≥400 ng/mL, portal vein tumor thrombus (PVTT), extrahepatic disease extension, and a neutrophil-to-lymphocyte ratio ≥5 each emerged as independent predictors of inferior PFS. Shorter OS was independently linked to ECOG 2, Child-Pugh class B, elevated AFP, PVTT, and distant metastases. Across both endpoints, the combination strategy retained independent prognostic significance (both <i>p</i> < 0.001). Serious immune-mediated toxicity (grades 3 and 4) was recorded in 15.1% of patients; 9.5% required permanent ICI discontinuation, and no fatality attributable to treatment was observed.</p><p><strong>Conclusions: </strong>In this real-world retrospective series, the integration of ICIs into TACE-based treatment was associated with meaningful gains in tumor response and survival among patients with intermediate-to-advanced HCC, without generating unacceptable safety signals. Stratification by functional status, hepatic functional reserve, AFP burden, vascular invasion, metastatic spread, and inflammatory markers may enhance individualized prognostic assessment in this population.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785261453478"},"PeriodicalIF":2.1,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148018959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Perioperative ¹⁷⁷Lutetium-Labeled Targeted Radionuclide Therapy on Inflammatory Response and Intestinal Recovery in Colorectal Cancer.","authors":"Jianhua Sun, Yong Zhang, Sai Zhang","doi":"10.1177/10849785261450842","DOIUrl":"https://doi.org/10.1177/10849785261450842","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of perioperative ¹⁷⁷Lutetium (¹⁷⁷Lu)-labeled anticarcinoembryonic antigen (CEA)-targeted radionuclide therapy (TRT) on perioperative inflammatory response, intestinal function recovery, pain control, dosimetric safety, and postoperative complications in colorectal cancer surgery patients within a precision oncology framework.</p><p><strong>Methods: </strong>A retrospective analysis of 72 patients who underwent elective radical colorectal cancer surgery (January 2022-December 2023). Patients were divided into a TRT group and a control group (36 cases each). The TRT group received ¹⁷⁷Lu-labetuzumab (1.85 GBq) 48 h preoperatively and a consolidation dose (0.74 GBq) at 24 h postoperatively; the control group received equivalent saline. Perioperative inflammatory markers [C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), white blood cell, neutrophil percentage], intestinal function recovery, visual analogue scale (VAS) pain scores, analgesic medication usage, dosimetric parameters, nutritional indicators, and postoperative complications were compared.</p><p><strong>Results: </strong>Baseline characteristics were comparable between groups (<i>p</i> > 0.05). Compared with the control group, the TRT group showed significantly lower inflammatory markers on postoperative days 3 and 7 (<i>p</i> < 0.05), shorter bowel sound recovery time (18.4 ± 6.7 h vs. 26.8 ± 8.9 h), first flatus time (28.6 ± 9.3 h vs. 42.1 ± 12.7 h), and defecation time (58.7 ± 18.4 h vs. 78.9 ± 22.6 h) (<i>p</i> < 0.001). VAS scores at all time points were significantly lower (<i>p</i> < 0.001), with reduced analgesic consumption. Tumor-absorbed dose was 32.7 ± 8.4 Gy with critical organ doses within International Commission on Radiological Protection tolerance. No serious radiotoxic adverse reactions occurred.</p><p><strong>Conclusions: </strong>In this retrospective exploratory study of imaging-selected colorectal cancer patients, perioperative ¹⁷⁷Lu-labeled anti-CEA TRT was associated with lower postoperative inflammatory marker levels, faster recovery of intestinal function, reduced analgesic requirements, and an acceptable short-term safety profile. These findings suggest that perioperative TRT may have potential short-term benefits in carefully selected patients, but prospective studies are required before broader clinical adoption.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785261450842"},"PeriodicalIF":2.1,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148018961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the Therapeutic Window in Oncology: Modern Strategies and Future Directions.","authors":"Shital Dange, Mohammed Musharraf Ali, Mamatha Gavisiddaiah, Jaffer Sadik Mohamed, Nasreen Sulthana, Roja Pathakota, Chandrika Balija","doi":"10.1177/10849785261445412","DOIUrl":"https://doi.org/10.1177/10849785261445412","url":null,"abstract":"<p><p><i>Background:</i>The enhancement of the therapeutic window (TW) in oncology remains a significant challenge, as the majority of anticancer treatments face difficulties in achieving optimal tumor control while minimizing adverse effects. Traditional chemotherapeutic agents, while demonstrating efficacy, are constrained by their limited TWs and the occurrence of systemic adverse effects.<i>Objective:</i> Recent advancements in precision medicine have revolutionized this paradigm by facilitating targeted tumor intervention via molecularly guided therapies, immuno-oncology strategies, and biomarker-driven patient classification. Novel approaches, including nanomedicine, antibody-drug conjugates, and prodrug formulations, improve therapeutic selectivity through the optimization of drug delivery, biodistribution, and release kinetics.<i>Methodology:</i> The concurrent advancements in radiotherapy, adaptive dosing methodologies, and toxicity assessment instruments have expanded the potential to enhance treatment intensity while preserving the integrity of normal tissues. In the future, the convergence of artificial intelligence (AI), multiomics profiling, and systems biology is anticipated to enhance therapeutic decision-making and expedite the creation of more personalized and adaptive interventions.<i>Results:</i>The efficacy of cancer treatments is substantially limited by notable shortcomings in research, despite progress in precision oncology. Tumor heterogeneity, the emergence of resistance mechanisms, and the absence of reliable biomarkers for anticipating treatment outcomes present significant impediments. The utilization of multiomics data and AI in clinical decision-making remains in its early stages, constrained by limitations in data validation and standardization. Furthermore, the translation of transdisciplinary concepts into accessible treatments is crucial, especially in environments with limited resources. Consequently, addressing these multifaceted issues is essential for improving the efficacy and safety of cancer treatments.<i>Conclusion:</i>This review integrates contemporary strategies and examines prospective pathways for expanding the TW, highlighting the intersection of technology, biology, and clinical innovation in the progression of cancer treatment.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785261445412"},"PeriodicalIF":2.1,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Oncology with ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer.","authors":"Fayou Zhou, Yongqing Zheng, Liang Huang, Xiaolei Tang, Liwei Yang, Sheng Shao","doi":"10.1177/10849785261447847","DOIUrl":"https://doi.org/10.1177/10849785261447847","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate the treatment response status in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) receiving &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 radioligand therapy within a precision oncology framework, analyze the incidence, depth, and influencing factors of PSA and radiological response, and provide scientific evidence for developing individualized treatment selection and optimization strategies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A cross-sectional survey study was conducted, including 182 elderly patients (age ≥65 years, having completed ≥2 cycles of &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 therapy) with prostate-specific membrane antigen (PSMA)-positive mCRPC confirmed by &lt;sup&gt;68&lt;/sup&gt;Ga-PSMA-11 Positron emission tomography/Computed tomography (PET/CT). Standardized assessment tools, including the Functional Assessment of Cancer Therapy-Prostate (FACT-P), Brief Pain Inventory-Short Form, and Hospital Anxiety and Depression Scale, were used to evaluate treatment response, quality of life, and mental health. The Common Terminology Criteria for Adverse Events was applied to grade treatment-related toxicities. Univariate analysis was performed to screen influencing factors, and multivariate logistic regression analysis was conducted to identify independent predictors of treatment response.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The overall PSA50 response rate (≥50% PSA decline) was 63.7% (116/182). Moderate response (50%-89% PSA decline) accounted for 39.6%, and deep response (≥90% PSA decline) accounted for 24.2%. Radiological partial or complete response was achieved in 42.3% of patients. Patients in the response group showed significantly higher FACT-P total scores (115.6 ± 18.4 versus 84.2 ± 17.8, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) and lower anxiety, depression, and pain scores compared with the nonresponse group. Multivariate analysis identified baseline hemoglobin &lt; 100 g/L (OR = 2.19, 95% CI: 1.05-4.57), prior docetaxel exposure (OR = 2.18, 95% CI: 1.07-4.44), high tumor burden ≥ 10 lesions (OR = 2.35, 95% CI: 1.18-4.67), PSMA SUVmax &lt; 12 (OR = 2.39, 95% CI: 1.11-5.14), and baseline alkaline phosphatase (ALP) &gt; 200 U/L (OR = 2.13, 95% CI: 1.03-4.37) as independent predictors of treatment nonresponse. PSA50 response rate showed a significant increasing trend with the number of therapy cycles administered (χ&lt;sup&gt;2&lt;/sup&gt;trend = 5.214, &lt;i&gt;p&lt;/i&gt; = 0.022).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Elderly mCRPC patients undergoing &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 radioligand therapy achieve meaningful PSA50 response rates, with baseline hemoglobin, prior docetaxel exposure, tumor burden, PSMA expression level, and ALP being independent predictors of response. Treatment response is closely associated with improved quality of life and mental health outcomes, with response rates improving with additional therapy cycles. These findings provide evidence-based guidance for precision patient selection, treatment monitoring, and individualized optimization st","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785261447847"},"PeriodicalIF":2.1,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiopharmaceutical-Guided Personalized Adjuvant Radiotherapy Planning after Esophageal Cancer Resection.","authors":"Zhida Fu, Yinghui Fang, Dapeng Wang, Jianxin Zuo, Shuaishuai Xiao, Jingyang Si","doi":"10.1177/10849785261443946","DOIUrl":"https://doi.org/10.1177/10849785261443946","url":null,"abstract":"<p><strong>Background: </strong>Esophageal cancer often has a significant locoregional recurrence risk after curative resection. Conventional postoperative radiation is largely based on anatomical imaging, which may not adequately detect microscopic residual disease or biological tumor heterogeneity.</p><p><strong>Purpose/hypothesis: </strong>The incorporation of radiopharmaceutical-guided molecular imaging enables biologically adaptive dosage adjustment.</p><p><strong>Population/subjects: </strong>The study assesses the feasibility and therapeutic efficiency of radionuclide-informed individualized adjuvant radiation planning following esophageal cancer resection.</p><p><strong>Assessment: </strong>Positron Emission Tomography (PET)/Computed Tomography (CT) imaging with tumor-specific tracers enabled the identification of biological targets.</p><p><strong>Statistical tests: </strong>Voxel-based dose painting was used, and plans were compared using the conformity index (CI), homogeneity index, V95% coverage, tumor control probability (TCP), and normal tissue complication probability (NTCP). Radiopharmaceutical imaging revealed additional high-risk areas in 34.7% of patients. Personalized planning increased the CI (1.21 to 0.97), V95% (91.2% to 97.8%), and TCP (68.4% to 82.9%). Mean lung and heart doses decreased by 14.3% and 11.7%, respectively, decreasing the predicted NTCP for pneumonitis from 16.5% to 9.2% (<i>p</i> < 0.001).</p><p><strong>Results: </strong>Radionuclide-guided personalized adjuvant radiation improves biological target coverage, increases TCP, and minimizes normal tissue toxicity, hence confirming its role in precision postoperative management of esophageal cancer.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785261443946"},"PeriodicalIF":2.1,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147822914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Noncanonical Hedgehog Signaling Exerts a Tumor-Promoting Effect on Pancreatic Cancer Cells Via Induction of Osteopontin Expression.","authors":"Weijiang Wu, Hanqing Yang, Zhutao Wang, Zhijian Zhang, Xiaodong Lu, Wenjing Yang, Xiayue Xu, Yinuo Jiang, Yan Li, Xin Fan, Qixiang Shao","doi":"10.1089/cbr.2021.0317","DOIUrl":"10.1089/cbr.2021.0317","url":null,"abstract":"<p><strong>Objective: </strong>Sonic Hedgehog (Shh)-Gli1 signaling and osteopontin (<i>OPN</i>) play vital roles in pancreatic cancer. However, the precise mechanisms of both signals have not been fully clarified, and whether there is a correlation between them in pancreatic ductal adenocarcinoma (PDAC) is unknown. This study aims to confirm the effect of <i>OPN</i> on human PDAC and assess whether Hh signaling affects pancreatic cancer cells through upregulation of <i>OPN</i>.</p><p><strong>Materials and methods: </strong><i>OPN</i> expression in human PDAC tissues and cell lines was investigated. Proliferation, apoptosis, migration, and invasion of <i>OPN</i>-knockdown BxPC-3 cells were observed. We analyzed the correlation between <i>Shh</i> or <i>Gli1</i> and <i>OPN</i> expression in human PDAC. Hh signaling inhibitors and shRNA against <i>Gli1</i> were used to confirm if <i>OPN</i> expression in BxPC-3 cells was regulated by Hh canonical or noncanonical pathway. We also evaluated the proliferation, apoptosis, migration, and invasion of <i>Gli1</i>-knockdown BxPC-3 cells.</p><p><strong>Results: </strong><i>OPN</i> is highly expressed in human PDAC tissues and cell lines. The proliferation, migration, and invasion of BxPC-3 cell lines were decreased, whereas apoptosis was increased when <i>OPN</i> was knocked down. Correlation analysis showed that <i>Gli1</i>, but not <i>Shh</i>, was associated with <i>OPN</i> expression in human PDAC, and <i>Gli1</i> regulated <i>OPN</i> production in BxPC-3 cells through a noncanonical pathway because <i>Gli</i> but not Smo inhibitor reduced <i>OPN</i> expression. Similar to above, the proliferation, migration, and invasion of BxPC-3 cells were decreased, whereas the apoptosis was increased when <i>Gli1</i> was knocked down. Supplement of exogenous OPN protein could partially reverse the effect of both <i>OPN</i> knockdown and <i>Gli1</i> knockdown on the bio-behavior of BxPC-3 cells.</p><p><strong>Conclusion: </strong>Hh signaling promotes proliferation, migration, and invasion but inhibits apoptosis of pancreatic cancer cells through upregulation of <i>OPN</i> in a noncanonical pathway.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"292-304"},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39870438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor-Associated Macrophage-Derived Exosomes Promote Progression of Gastric Cancer by Regulating P38MAPK Signaling Pathway and Immune Checkpoint PD-L1.","authors":"Yusheng Wang, Kun Shang, Ninggang Zhang, Jian Zhao, Bangwei Cao","doi":"10.1089/cbr.2021.0218","DOIUrl":"10.1089/cbr.2021.0218","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of M2 macrophage-derived exosomes (M2-Exos) on proliferation, migration, and apoptosis of gastric cancer cells in the tumor microenvironment and to further explore their possible molecular mechanism.</p><p><strong>Materials and methods: </strong>M2 macrophages were induced from THP-1 cells and identified by qRT-PCR. Exosomes were extracted by ultracentrifugation and identified by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot analysis. Fluorescence labeling was used to detect the internalization of exosomes in receptors. The proliferation, migration, and invasion of AGS and HGC27 cells were determined by EdU and MTS, wound healing and Transwell assay, and flow cytometry, respectively. Proteins in the related pathway of M2-Exos affecting the progression of gastric cancer were detected by Western blot analysis.</p><p><strong>Results: </strong>In this study, M2 macrophages and M2-Exos were successfully obtained. The purified M2-Exos were observed as small round vesicles with diameters of 50-90 nm and positive expression of CD63, CD9, and TSG101. Besides, M2-Exos can be effectively taken up and internalized by AGS and HGC27 cells. Cell behavior studies showed that M2-Exos promoted proliferation and migration and inhibited the apoptosis of AGS and HGC27. Further research illustrated that M2-Exos promoted the phosphorylation of P38 and high expression of programmed death ligand 1 (PD-L1).</p><p><strong>Conclusions: </strong>This study demonstrated that M2-Exos promoted proliferation and migration and inhibited the apoptosis of gastric cancer cells. Mechanically, M2-Exos may promote gastric cancer progression through the P38MAPK signaling pathway and achieve immune escape through elevating the expression of PD-L1.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"337-347"},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39558283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transthyretin Suppressed Tumor Progression in Nonsmall Cell Lung Cancer by Inactivating MAPK/ERK Pathway.","authors":"Dong-Bin Wang, Xuan Li, Xi-Ke Lu, Zhong-Yi Sun, Xun Zhang, Xia Chen, Lan Ma, Hong-Gang Xia","doi":"10.1089/cbr.2021.0261","DOIUrl":"10.1089/cbr.2021.0261","url":null,"abstract":"<p><strong>Background: </strong>Lung malignancy is a main source of disease passing all throughout the planet, whereas the transthyretin (TTR) is a specific biomarker for clinical diagnosis. However, its role in lung malignancy stays to be obscure.</p><p><strong>Materials and methods: </strong>In the current study, the authors made an endeavor to research impact of abnormal expression of TTR on nonsmall cell lung carcinoma (NSCLC) by overexpression or knockdown of TTR. To further explore the instruments' fundamental mechanism part of TTR in NSCLC, several signal pathways were searched and verified. To confirm the effect of TTR overexpression on tumors, <i>in vivo</i> experiments were conducted.</p><p><strong>Results: </strong>It was found that upregulated TTR clearly stifled cell proliferation, migration, invasion, and expanded apoptosis. Significant suppression of phosphor-extracellular signal-regulated kinase (ERK) was observed in TTR-treated NSCLC cells, implying that TTR was important for cellular progress by regulating mitogen-activated protein kinase/ERK signaling pathway. In <i>in vivo</i> experiment, overexpression of TTR promoted cell apoptosis and inhibited tumor growth.</p><p><strong>Conclusion: </strong>Overall, the results suggest that TTR has a potential antitumor effect in human NSCLC progression, which provides theoretical basis for the diagnosis and treatment of NSCLC. Above all, further understanding of TTR was useful for clinical care.</p><p><strong>Clinical trial registration number: </strong>2016-08.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"328-336"},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39561582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin Suppresses Cell Proliferation, Migration, and Invasion Through Modulating miR-21-5p/<i>SOX6</i> Axis in Hepatocellular Carcinoma.","authors":"Chunguang Zhou, Chao Hu, Bing Wang, Sunfu Fan, Wangxun Jin","doi":"10.1089/cbr.2020.3734","DOIUrl":"10.1089/cbr.2020.3734","url":null,"abstract":"<p><strong>Background: </strong>Curcumin is the major component of turmeric, which has an anticancer property in multiple cancers, including hepatocellular carcinoma (HCC). However, the mechanisms are still largely unclear. This research aims to assess the pharmacological function of curcumin and explore the potential microRNA (miRNA)-mRNA regulatory mechanism in curcumin-mediated HCC progression.</p><p><strong>Materials and methods: </strong>Hep3B and Huh-7 cells were used for <i>in vitro</i> experiments. Cells were exposed to various doses of curcumin, and transfection was conducted using Lipofectamine 2000. Cell proliferation, migration, and invasion were examined using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide or transwell assay. The abundances of miR-21-5p and sex-determining region Y-related high-mobility group box 6 (<i>SOX6</i>) were examined using quantitative real-time polymerase chain reaction or Western blot. The relationship between miR-21-5p and <i>SOX6</i> was analyzed through luciferase reporter analysis.</p><p><strong>Results: </strong>Curcumin repressed HCC cell proliferation, migration, and invasion. miR-21-5p level was decreased in curcumin-treated cells, and miR-21-5p overexpression reversed curcumin-mediated inhibition of HCC progression. <i>SOX6</i> was targeted through miR-21-5p, and <i>SOX6</i> restoration attenuated miR-21-5p-induced promotion of HCC progression. Moreover, curcumin exposure increased <i>SOX6</i> expression through regulating miR-21-5p, and knockdown of <i>SOX6</i> overturned curcumin-modulated suppression of HCC progression.</p><p><strong>Conclusions: </strong>Curcumin repressed proliferation, migration, and invasion of HCC cells by regulating miR-21-5p and <i>SOX6</i>, indicating the promisingly pharmacological effect of curcumin in HCC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"319-327"},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38242064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}